Tenidap

Tenidap is a nonsteroidal anti-inflammatory drug (NSAID) that was developed by Pfizer in the late 1980s and early 1990s. It was designed to treat rheumatoid arthritis and osteoarthritis, but was withdrawn from the market due to concerns about its safety profile.

History

Pfizer began developing Tenidap in the late 1980s as a new type of NSAID that could potentially offer better efficacy and fewer side effects than existing treatments for rheumatoid arthritis and osteoarthritis. The drug was designed to inhibit both the cyclooxygenase (COX) and lipoxygenase (LOX) pathways, which are involved in the inflammatory response.

In the early 1990s, Tenidap entered clinical trials and showed promising results in reducing pain and inflammation in patients with rheumatoid arthritis and osteoarthritis. However, during the later stages of clinical trials, concerns were raised about the drug's safety profile, particularly its potential to cause liver damage.

Despite these concerns, Pfizer applied for approval from the Food and Drug Administration (FDA) in the United States in 1996. However, the FDA declined to approve the drug, citing concerns about its safety profile. Following this decision, Pfizer withdrew Tenidap from the market.

Pharmacology

Tenidap is a dual inhibitor of the COX and LOX pathways, which are involved in the inflammatory response. By inhibiting these pathways, Tenidap can reduce inflammation and pain in patients with rheumatoid arthritis and osteoarthritis.

In addition to its anti-inflammatory effects, Tenidap also has analgesic and antipyretic effects. However, the drug's potential to cause liver damage has limited its use in clinical practice.

See also

• Nonsteroidal anti-inflammatory drug
• Rheumatoid arthritis
• Osteoarthritis
• Pfizer